Synthetic Biology and Nanotechnology Group

Brasília, Brazil

Synthetic Biology and Nanotechnology Group

Brasília, Brazil
SEARCH FILTERS
Time filter
Source Type

da Cunha N.B.,Synthetic Biology and Nanotechnology Group | Murad A.M.,Synthetic Biology and Nanotechnology Group | Vianna G.R.,Synthetic Biology and Nanotechnology Group | Coelho C.,Synthetic Biology and Nanotechnology Group | Rech E.L.,Synthetic Biology and Nanotechnology Group
Current Pharmaceutical Design | Year: 2013

Seeds are organs specialised in accumulating proteins, and they may provide a potential economically viable platform for the large-scale production and storage of many molecules for pharmaceutical and other productive sectors. Soybean [Glycine max (L.) Merrill] has a high seed protein content and represents an excellent source of abundant and cheap biomass. Under greenhouse conditions and a daily photoperiod of 23 h of light, the soybean plant's vegetative growth can be significantly extended by inducing more than a tenfold increase in seed production when compared with plants cultivated under field conditions. Some factors involved in the production of different recombinant proteins in soybean seeds are discussed in this review. These include transgenic system, regulatory sequences and the use of Mass Spectrometry as a new tool for molecular characterisation of seed produced recombinant proteins. The important intrinsic characteristics and possibility of genetically engineering soybean seeds, using current advances in recombinant DNA technology including metabolic engineering and synthetic biology, should form the foundation for large-scale and more precise genome modification, making this crop an important candidate as bioreactor for production of recombinant molecules. © 2013 Bentham Science Publishers.


Rech E.L.,Synthetic Biology and Nanotechnology Group | Arber W.,University of Basel
Annals of Applied Biology | Year: 2013

Plant and animal domestication form the foundation of agriculture. Currently, there are considerable efforts and hypotheses to understand adaptation and regulatory processes involving domestication and biodiversity organisms. Here, we propose the use of recombinant DNA as a foundation for the synthetic domestication of biodiversity traits. For example, we commented on current studies involving synthetic spider-like fibres production in bacteria and mimicking oil seed species in genetically manipulated soybean. We suggest that this approach constitutes a sustainable and viable option for conservation and development of value-added processes and products from biodiversity. © 2013 Association of Applied Biologists.


da Cunha N.B.,Synthetic Biology and Nanotechnology Group | Vianna G.R.,Synthetic Biology and Nanotechnology Group | da Almeida Lima T.,Synthetic Biology and Nanotechnology Group | Rech E.,Synthetic Biology and Nanotechnology Group
Biotechnology Journal | Year: 2014

Plants have emerged as an attractive alternative to the traditional mammalian cell cultures or microbial cell-based systems system for the production of valuable recombinant proteins. Through recombinant DNA technology, plants can be engineered to produce large quantities of pharmaceuticals and industrial proteins of high quality at low costs. The recombinant production, by transgenic plants, of therapeutic proteins normally present in human plasma, such as cytokines, coagulation factors, anticoagulants, and immunoglobulins, represents a response to the ongoing challenges in meeting the demand for therapeutic proteins to treat serious inherited or acquired bleeding and immunological diseases. As the clinical utilization of fractionated plasma molecules is limited by high production costs, using recombinant biopharmaceuticals derived from plants represents a feasible alternative to provide efficient treatment. Plant-derived pharmaceuticals also reduce the potential risks to patients of infection with pathogens or unwanted immune responses due to immunogenic antigens. In this review, we summarize the recent advances in molecular farming of cytokines. We also examine the technological basis, upcoming challenges, and perspectives for the biosynthesis and detection of these molecules in different plant production platforms. © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.


PubMed | Synthetic Biology and Nanotechnology Group
Type: Journal Article | Journal: Biotechnology journal | Year: 2014

Plants have emerged as an attractive alternative to the traditional mammalian cell cultures or microbial cell-based systems system for the production of valuable recombinant proteins. Through recombinant DNA technology, plants can be engineered to produce large quantities of pharmaceuticals and industrial proteins of high quality at low costs. The recombinant production, by transgenic plants, of therapeutic proteins normally present in human plasma, such as cytokines, coagulation factors, anticoagulants, and immunoglobulins, represents a response to the ongoing challenges in meeting the demand for therapeutic proteins to treat serious inherited or acquired bleeding and immunological diseases. As the clinical utilization of fractionated plasma molecules is limited by high production costs, using recombinant biopharmaceuticals derived from plants represents a feasible alternative to provide efficient treatment. Plant-derived pharmaceuticals also reduce the potential risks to patients of infection with pathogens or unwanted immune responses due to immunogenic antigens. In this review, we summarize the recent advances in molecular farming of cytokines. We also examine the technological basis, upcoming challenges, and perspectives for the biosynthesis and detection of these molecules in different plant production platforms.

Loading Synthetic Biology and Nanotechnology Group collaborators
Loading Synthetic Biology and Nanotechnology Group collaborators